Born in Milan in 1955, Sergio Dompé is an entrepreneur in the pharmaceutical and biotechnological industries and President of Dompé, a pharmaceutical group developing innovative therapeutic solutions for rare and orphan diseases. 

He has been awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010).

Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centers for diseases in Dompé’s main therapeutic fields.

In 2016, he funded and established Movendo, an innovative medical company sparkled by an idea by the Italian Institute of Technology: to develop advanced technologies at the service of mankind and products in the field of physical movement rehabilitation. 

In 2004 he was awarded the “La Lombardia per il lavoro” prize, in recognition of his value as one of Lombardy’s most innovative entrepreneurs.

In 2016, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.),  awarded to those who distinguished themselves in the research field.

In 2017 he was awarded the Guido Carli Prize. 

Institutional offices held:

• From 1998 to 2004: President of Assobiotec 

• Since 2004: anchor investor in Philogen, a leader in the research and development of antibodies 

• From 2005 to 2011: President of Farmindustria 

• From 2006 to 2011: Chairman of the Evaluation Committee of the CNR (Consiglio Nazionale delle Ricerche, National Research Council) 

• From 2007 to 2015: member of the Board of the IIT (Italian Institute of Technology) Foundation 

• From 2014 to 2016: member of the Patent Experts Committee of the CNR 

• From 2014 to 2016: member of the Board of Regency of the Bank of Italy (Milan office) 

• Since 2015: member of the General Council of Confindustria as representative of Farmindustria 

• Since 2016: Censor of the Bank of Italy (Milan office) 

• Since 2019: Vice President of Assolombarda with delegated powers over Life Sciences 

• 2020: Chairman of the 2021 B20 Life Sciences task-force

After earning his degree in Biology in 1997 from the University of Naples “Federico II” and completing a PhD in Biochemistry and Molecular Biology at the same institution in 2001, Enrico Bucci carried out research in molecular and structural biology, including work at the Institut für Molekulare Biotechnologie in Jena (now the Leibniz Institute on Aging – Fritz Lipmann Institute). In 2001 he was appointed researcher at the Institute of Biostructures and Bioimaging of the Italian National Research Council, where he worked until 2014.

He later held academic and scientific positions in Italy and abroad, and he is currently an Adjunct Professor of Biology at Temple University (Philadelphia) and director of a research program at the Sbarro Health Research Organization (Philadelphia). Alongside his academic work, he founded and led several entrepreneurial initiatives in biotechnology and bioinformatics, served as scientific director for various companies, and is now CEO of Resis Srl, a company focused on data analysis and scientific research integrity.

He is internationally recognized as an expert in research integrity, working as a consultant for academic institutions, research organizations, major companies, and scientific publishers. His work includes analyzing complex cases of data manipulation and developing tools to assess the reliability of scientific publications.

He is the author of more than 100 peer‑reviewed papers and around a dozen international patents.

Alongside his scientific activity, he is deeply engaged in science communication and critical analysis of the research system, contributing articles, public talks, and books on the scientific method, distortions in the research ecosystem, and the relationship between science and society. His published works include Cattivi scienziati (2015, new edition 2020), Geni, memi e bit (2024), and Lessico del pensiero critico (2026) with Gilberto Corbellini.

With a degree in Medical Chemistry from The Sapienza University of Rome, Marcello is a member of the American Chemical Society since 1988 and the Italian Chemistry Society since 2006.

After a brief period spent as a university researcher, he joined Dompé taking on increasingly relevant roles: first as a team leader, then as Research Director, until his current position as Chief Scientific Officer, a role he has held since 2009.

He leads Dompe’s Research and Development activities and pre-clinical and clinical drug development programs - from active ingredient identification to market authorization - including relationships with international regulatory authorities.

In parallel with his involvement in the company, Marcello has filed more than 30 international patents. His work has been published in numerous international scientific journals, for some of which he serves as Associate Editor.

Alessandro Vespignani is Sternberg Family Distinguished University Professor at Northeastern University, where he directs the Network Science Institute. In Italy, he currently serves as President of Fondazione ISI in Turin. 

His research lies at the intersection of computational modeling, data science, and complex systems, with a focus on contagion phenomena such as epidemics, information diffusion, and collective behavior. He currently leads EPISTORM, a center funded by the U.S. CDC, a national project to develop the next generation of analytical tools for epidemic emergencies. 

His work has been published in leading international scientific journals, including Nature, Science, and PNAS. He has received numerous international awards, including the EPS-SNPD Prize from the European Physical Society and the Euler Award from the Network Science Society. He is the author of popular science books, including "L'algoritmo e l'oracolo" and "I piani del nemico." He is an Honorary Fellow of the American Physical Society, the Network Science Society, and the American Association for the Advancement of Science.

Graduated in Pharmaceutical Chemistry and Technology from the University of Milan, she has been leading the IP & Strategic Intelligence department at Dompé Farmaceutici since 2019. A European and Italian patent attorney, she has extensive experience in leveraging innovation and defining intellectual property strategies supporting pharmaceutical research.

Throughout her career, she has worked both in industry and in private practice, developing an integrated approach that combines scientific, legal, and strategic expertise. Prior to entering the patent attorney profession, she conducted scientific research at leading international academic institutions, including Columbia University in New York and Guy’s Hospital in London.